Drug Delivery Business

Medtronic

Medtronic warns on button glitch with MiniMed 640G insulin pump

By

Medtronic (NYSE:MDT) issued a field safety notice in May, warning users that keypad buttons on its MiniMed 640G insulin pump may become temporarily stuck when the atmospheric pressure around the pump suddenly increases or decreases – like during air travel. If the keypad buttons are stuck, users may not be able to program a bolus or […]

Medtech stories we missed this week: June 9, 2017

By

From 3M’s expanded 510(k) clearance for its Tegaderm dressing to Medtronic and Acacia burying the hatchet, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. InspireMD inks Taiwanese distro deal for CGuard InspireMD announced in a June 8 press release that it has signed a distribution deal with […]

Diabetes double play: Medtronic launches MiniMed 670G, Dexcom wins FDA nod for Android G5 app

By

Medtronic (NYSE:MDT) and Dexcom (NSDQ:DXCM) today announced respective wins for their diabetes care tech, with Medtronic launching its hybrid closed loop MiniMed 670G in the US and Dexcom winning an FDA nod for a Google (NSDQ:GOOG) Android G5 Mobile application. Fridley, Minn.-based Medtronic’s MiniMed 670G is designed to automatically track and adjust blood sugar levels in patients […]

Medtronic launches opioid-induced respiratory depression study

By

Medtronic (NYSE:MDT) said today that it’s starting a large study on the effect of pulse oximetry and capnography in opioid-induced respiratory depression, using its Capnostream device. The 1,650-patient Prodigy study aims to create a tool to score the risk of OIRD in patients being treated with opioids for pain, using Capnostream’s continuous pulse oximetry and capnography monitoring […]

Artificial pancreas: These companies are racing to make one

By

Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in the newest video from editors at Drug Delivery Business’s sister publication Medical Design & Outsourcing. (And for a deeper dive, check out […]

Medtronic launches study of In.Pact Admiral drug-coated balloon in end-stage renal disease

By

Medtronic (NYSE:MDT) said today that the 1st patient was enrolled in a study of its In.Pact Admiral drug-coated balloon in patients with end-stage renal disease. The FDA approved the investigational device exemption study to evaluate the device as a treatment for failing arteriovenous fistulas in end-stage renal disease patients. “We are delighted to enroll and treat […]

EuroPCR Roundup: Bioresorbable stents show promise, but metallic drug-eluting stents remain standard

By

Updated to include a statement from an Abbott spokesperson.  Abbott‘s (NYSE:ABT) bioresorbable scaffold has been plagued with a myriad of troubling data, including a study that showed that the device is associated with an increase in thrombosis and target lesion failure. In April, Abbott restricted use of the Absorb devices to clinical registry studies. In response […]

Medtronic wins FDA nod for Resolute Onyx drug-eluting stent

By

Medtronic (NYSE:MDT) said today that the FDA approved its Resolute Onyx drug-eluting stent. The Fridley, Minn.-based company touted its device as the 1st stent formed by a sinusoidal wave of cobalt alloy wire. The company incorporated a radiopaque inner core within the wire to boost visibility, according to Medtronic. The stent also features thin struts and a polymer […]

Boston Scientific looks to lead the drug-eluting PAD market

By

Angioplasty is not a new procedure – doctors have been widening obstructed arteries with balloons since the 1960s. But for years the medtech industry has been plagued with what Jeff Mirviss, president of Boston Scientific’s interventional peripheral biz, calls the procedure’s Achilles heel: Restenosis. For patients treated with bare balloons, half must have the procedure done again […]